Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,003 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.
Panka DJ, Buchbinder E, Giobbie-Hurder A, Schalck AP, Montaser-Kouhsari L, Sepehr A, Lawrence DP, McDermott DF, Cohen R, Carlson A, Wargo JA, Merritt R, Seery VJ, Hodi FS, Gunturi A, Fredrick D, Atkins MB, Iafrate AJ, Flaherty KT, Mier JW, Sullivan RJ. Panka DJ, et al. Among authors: carlson a. Mol Cancer Ther. 2014 Dec;13(12):3210-8. doi: 10.1158/1535-7163.MCT-14-0349. Epub 2014 Oct 15. Mol Cancer Ther. 2014. PMID: 25319388 Free PMC article.
FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.
Erbe AK, Wang W, Goldberg J, Gallenberger M, Kim K, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng SC, Signoretti S, Atkins M, Carlson A, Mier JW, Panka DJ, McDermott DF, Sondel PM. Erbe AK, et al. Among authors: carlson a. Clin Cancer Res. 2017 May 1;23(9):2159-2168. doi: 10.1158/1078-0432.CCR-16-1874. Epub 2016 Oct 14. Clin Cancer Res. 2017. PMID: 27742794 Free PMC article. Clinical Trial.
Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.
Wang W, Erbe AK, Gallenberger M, Kim K, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng SC, Signoretti S, Atkins M, Carlson A, Weiss JM, Mier J, Panka D, McDermott DF, Sondel PM. Wang W, et al. Among authors: carlson a. Cancer Immunol Immunother. 2016 Dec;65(12):1523-1532. doi: 10.1007/s00262-016-1904-8. Epub 2016 Sep 30. Cancer Immunol Immunother. 2016. PMID: 27695964 Free PMC article.
Malignant melanoma.
Slominski A, Wortsman J, Carlson AJ, Matsuoka LY, Balch CM, Mihm MC. Slominski A, et al. Among authors: carlson aj. Arch Pathol Lab Med. 2001 Oct;125(10):1295-306. doi: 10.5858/2001-125-1295-MM. Arch Pathol Lab Med. 2001. PMID: 11570904 Free article. Review.
Molecular pathology of soft tissue and bone tumors. A review.
Slominski A, Wortsman J, Carlson A, Mihm M, Nickoloff B, McClatchey K. Slominski A, et al. Among authors: carlson a. Arch Pathol Lab Med. 1999 Dec;123(12):1246-59. doi: 10.5858/1999-123-1246-MPOSTA. Arch Pathol Lab Med. 1999. PMID: 10583931 Free article. Review.
Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial.
Harris VK, Stark J, Williams A, Roche M, Malin M, Kumar A, Carlson AL, Kizilbash C, Wollowitz J, Andy C, Gerber LM, Sadiq SA. Harris VK, et al. Among authors: carlson al. Stem Cell Res Ther. 2024 May 23;15(1):151. doi: 10.1186/s13287-024-03765-6. Stem Cell Res Ther. 2024. PMID: 38783390 Free PMC article. Clinical Trial.
1,003 results